New drug combo tested for Tough-to-Treat breast cancer
NCT ID NCT07358377
Summary
This early-stage study is testing whether adding an experimental drug called HRS-6209 to standard hormone therapies (fulvestrant or letrozole) is safe and might help control advanced breast cancer. It will involve about 15 patients whose cancer has specific hormone receptor patterns and has spread or cannot be surgically removed. Researchers will closely monitor side effects and look for early signs that the combination can shrink tumors or slow the cancer's growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.